Famciclovir – 250 mg

Brand:
Cayman
CAS:
104227-87-4
Storage:
-20
UN-No:
Non-Hazardous - /

Famciclovir is an orally bioavailable prodrug form of the antiviral guanosine analog penciclovir (Item No. 22918).{39519} Famciclovir is rapidly deacetylated and oxidized in vivo to form penciclovir, which is active against clinical isolates of herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) in a plaque reduction assay with IC50 values of 1.6, 6, and 12 μM, respectively. Both famciclovir and the product of its deacetylation, 6-deoxypenciclovir, are oxidized in vitro by human, guinea pig, and rat liver aldehyde oxidase, with 6-deoxypenciclovir being converted to penciclovir.{39520} Peak plasma concentrations of penciclovir (mean 3.5 μg/ml) are reached 0.5 hours after oral administration of famciclovir (40 mg/kg) in rats.{39521} Famciclovir (25 mg/kg) has a longer half-life in dogs, with peak concentrations of penciclovir (mean 4.4 μg/ml) in plasma occurring after 3 hours.  

 

Available on backorder

SKU: 23834 - 250 mg Category:

Description

An orally bioavailable prodrug form of penciclovir; oxidized in vitro by human, guinea pig, and rat liver aldehyde oxidase; in rats the peak concentrations of penciclovir in plasma (mean 3.5 μg/ml) occur in 0.5 hours (40 mg/kg); in dogs the peak concentrations of penciclovir in plasma (mean 4.4 μg/ml) occur in 3 hours (25 mg/kg)


Formal name: 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol, 1,3-diacetate

Synonyms:  BRL 42810

Molecular weight: 321.3

CAS: 104227-87-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Chicken Pox & Shingles||Research Area|Infectious Disease|Viral Diseases|HSV